STOCK TITAN

Connect Biopharma to Report First Half 2022 Financial Results on September 13

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings

Rhea-AI Summary

Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced it will report financial results for the six months ending June 30, 2022, on September 13, 2022, after market close. The company will host a webcast and conference call at 1:30 p.m. PDT to discuss these results along with a corporate update. Connect Biopharma focuses on developing therapeutics for T cell-driven inflammatory diseases, with key candidates including CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis.

Loading...
Loading translation...

Positive

  • Company developing multiple therapeutic candidates targeting serious inflammatory diseases.
  • Lead product candidate CBP-201 targets IL-4Rα for atopic dermatitis and asthma.
  • Second candidate CBP-307 in development for ulcerative colitis.

Negative

  • None.
Argus Session date unavailable
+2.14% session move Open Argus
Details

News Market Reaction – CNTB

The recorded move for CNTB in the trading session of this news was +2.14%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT

SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report financial results for the six-month period ended June 30, 2022, on Tuesday, September 13, after market close. Following the press release, the Company will host a webcast and conference call at 1:30 p.m. PDT to discuss the financial results and provide a corporate update.

The news release will be posted to the investor relations section of Connect Biopharma’s website at: https://investors.connectbiopharm.com/investors.

About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Connect Biopharma report its financial results?

Connect Biopharma will report its financial results for the six months ended June 30, 2022, on September 13, 2022.

What is Connect Biopharma's lead product candidate?

The lead product candidate of Connect Biopharma is CBP-201, which targets interleukin-4 receptor alpha for treating atopic dermatitis and asthma.

Where can I find the webcast for Connect Biopharma's financial results?

The webcast for Connect Biopharma's financial results can be accessed via their investor relations website following the press release on September 13, 2022.

What diseases is Connect Biopharma targeting with its products?

Connect Biopharma is targeting various inflammatory diseases, including atopic dermatitis, asthma, and ulcerative colitis.

Keep reading